Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1028-1035

  Rothenberg, S Michael ^a,b   McFadden, David G ^a,b   Palmer, Edwin L ^b   Daniels, Gilbert H ^a,b   Wirth, Lori J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CREATININE; DABRAFENIB; IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; SELUMETINIB; THYROGLOBULIN; IMIDAZOLE DERIVATIVE; OXIME;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CANCER CELL; CANCER INCIDENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KERATOSIS; LYMPH NODE METASTASIS; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; SKIN CARCINOMA; SKIN DEFECT; THYROID CARCINOMA; TREATMENT RESPONSE; VERRUCOUS KERATOSIS; VERY ELDERLY; WEIGHT REDUCTION; ADJUVANT CHEMORADIOTHERAPY; CARCINOMA; CELL DIFFERENTIATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; RADIATION TOLERANCE; THYROID NEOPLASMS; TREATMENT OUTCOME; WHOLE BODY IMAGING; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; CARCINOMA; CELL DIFFERENTIATION; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMIDAZOLES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84929468523     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2915     Document Type: Article

References (25)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 2010; 322: 8-28.
3. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, et al. Both BRAF V600E mutation and older Age (>/ = 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011; 18: 3566-71.
4. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-70.
5. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
6. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-501.
7. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937-41.
8. Schlumberger MJ Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
9. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-60.
10. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009; 115: 972-80.
11. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-69.
12. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 511-20.
13. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65: 4238-45.
14. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005; 65: 2465-73.
15. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009; 69: 8317-25.
16. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121: 4700-11.
17. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623-32.
18. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146-58.
19. Brose MS, Christopher N, Barbara J, Rossella E, Salvatore S, Lars B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. Lancet 2014; 384: 319-28.
20. Schulmberger M. Sorafenib side effects not inconsequential in thyroid cancer [abstract]. In: Proceedings of the 83rd Annual Meeting American Thyroid Association; 2013 Oct 23. Abstract nr 100.
21. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996; 37: 1557-62.
22. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131 I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-72.
23. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3: 520-33.
24. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
25. McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 2014; 111:E1600-9.